Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Jun 29 2024 | New Episode of the Heart Failure Beat Discusses HFpEF HFSA News Podcasts Provider Education Read More Jun 25 2024 | Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations Industry News In The News Industry Read More Jun 3 2024 | BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting Industry News In The News Industry Read More Jun 3 2024 | Welcoming May's New HFSA Members HFSA News Membership Read More May 29 2024 | HFSA Recommends Medicare Coverage of Implantable Hemodynamic Monitoring for HF Practice News Advocacy In The News Read More Pagination First page « First Previous page ‹ Previous … Page 6 Page 7 Page 8 Page 9 Current page 10 Page 11 Page 12 Page 13 Page 14 … Next page Next › Last page Last »
Jun 29 2024 | New Episode of the Heart Failure Beat Discusses HFpEF HFSA News Podcasts Provider Education Read More
Jun 25 2024 | Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations Industry News In The News Industry Read More
Jun 3 2024 | BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting Industry News In The News Industry Read More
May 29 2024 | HFSA Recommends Medicare Coverage of Implantable Hemodynamic Monitoring for HF Practice News Advocacy In The News Read More
